Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor ... Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors. Mehr anzeigen
First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.25 | -10.8695652174 | 2.3 | 2.3 | 1.91 | 1306094 | 2.05514421 | CS |
| 4 | -0.11 | -5.09259259259 | 2.16 | 2.605 | 1.83 | 1966110 | 2.17093074 | CS |
| 12 | -0.2 | -8.88888888889 | 2.25 | 3.39 | 1.67 | 1897141 | 2.31291136 | CS |
| 26 | -0.26 | -11.2554112554 | 2.31 | 3.39 | 1.67 | 1457373 | 2.27639591 | CS |
| 52 | -0.09 | -4.20560747664 | 2.14 | 11.48 | 1.67 | 2007110 | 4.17701666 | CS |
| 156 | -12.94 | -86.3242161441 | 14.99 | 47.2508 | 1.67 | 1261191 | 11.1280212 | CS |
| 260 | -16.6 | -89.0080428954 | 18.65 | 47.2508 | 1.67 | 1174929 | 11.24663194 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
